Karyopharm Therapeutics has been granted a patent for compounds and salts used in treating disorders related to CRM1 activity. The invention includes a specific compound represented by structural formula IV. GlobalData’s report on Karyopharm Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Karyopharm Therapeutics, Targeted cancer therapy was a key innovation area identified from patents. Karyopharm Therapeutics's grant share as of May 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of disorders associated with crm1 activity
The granted patent (Publication Number: US11945794B2) discloses a compound represented by structural formula IV, with various optional substitutions for R2, including heteroaryl groups with nitrogen, oxygen, and sulfur atoms. The patent further specifies specific heteroaryl groups such as pyrrolyl, furanyl, thiophenyl, and others that can be part of the compound. Additionally, the patent covers compounds of structural formula III, with Rb groups selected from specific functional groups like —C(O)—OH or —C(O)—NH2, and R2 being an optionally substituted heteroaryl with specific heteroatoms.
Moreover, the patent includes claims for pharmaceutically acceptable compositions containing the disclosed compounds or their salts, along with a pharmaceutically acceptable carrier. It also encompasses a method for promoting wound healing by administering a therapeutically effective amount of the compound to a subject in need. The compounds and compositions described in the patent are intended for use in wound healing applications, highlighting the potential pharmaceutical relevance of the disclosed inventions in the medical field.
To know more about GlobalData’s detailed insights on Karyopharm Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
